Meeting
2022 ASCO Annual Meeting
CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)—Results of an initial safety cohort.
Authors
Marcia Hall
Mount Vernon Cancer Centre, Northwood, United Kingdom
Marcia Hall , Karen Allan , Agnieszka Michael , Andrew R. Clamp , Rosalind Glasspool , Shibani Nicum , Rosemary Lord , Susana N. Banerjee , Joshua Roche , Jamie Stobo , Charlie Gourley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
ISRCTN10490346
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5577)
DOI
10.1200/JCO.2022.40.16_suppl.5577
Abstract #
5577
Poster Bd #
453
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.
First Author: Jun Ma
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee
Poster
2019 Genitourinary Cancers Symposium
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
First Author: Albert Font Pous
Poster
2018 ASCO Annual Meeting
A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
First Author: Daniel E. Castellano